This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Verhoog, L. C. Articles by Klijn, J.G.M. Search for Related Content PubMed PubMed Citation Articles by Verhoog, L. C. Articles by Klijn, J.G.M.

Survival in Hereditary Breast Cancer Associated With Germline Mutations of BRCA2

From the Family Cancer Clinic and Department of Medical Registration, Daniel den Hoed Cancer Center, University Hospital Rotterdam; Department of Clinical Genetics, Erasmus University Rotterdam, Rotterdam; and Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.

Address reprint requests to J.G.M. Klijn, MD, PhD, Family Cancer Clinic, Department of Medical Oncology, Daniel den Hoed Kliniek, Groene Hilledijk 301, 3075 EA Rotterdam, the Netherlands.

PURPOSE: Breast cancer in BRCA1 and BRCA2 gene-mutation carriers may differ from so-called sporadic breast cancer in clinical features and behavior. These potential differences may be of importance for the prevention, screening, and, ultimately, treatment of breast cancer in women with such germline mutations. Thus far, there have been very few studies on the survival of BRCA2-associated breast cancer patients.

PATIENTS AND METHODS: We determined the disease-free and overall survival of 28 breast cancer patients from 14 consecutive families with eight different BRCA2 germline mutations. These patients' survival and tumor characteristics were compared with those of a control group of 112 sporadic breast cancer patients matched to them by age and year of diagnosis.

RESULTS: The 5-year disease-free survival was 52% for each group (P = .91); the overall survival was 74% for BRCA2 carriers and 75% for sporadic cases (P = .50). At the time of diagnosis, tumors from the BRCA2 carriers were borderline significantly larger in comparison to the tumors in sporadic cases (P = .05), but axillary nodal status was not significantly different in the two groups (node-negativity, 63% v 52.8%, respectively; P = .34). With respect to steroid receptor status, BRCA2-associated tumors were more likely to be steroid receptor-positive, especially regarding progesterone receptor status (100% v 76.7% positive, respectively; P = .06). Stage-adjusted recurrence and death rates were nonsignificantly better for BRCA2 cases (hazard ratios of 0.84 and 0.59 [P = .61 and P = .19], respectively). In contrast, after 5 years, the rate of metachronous contralateral breast cancer in BRCA2 patients was 12% (v 2% in controls; P = .02).

CONCLUSION: Patients with hereditary breast cancer due to BRCA2 have a similar prognosis when compared with age-matched sporadic breast cancer patients. Contrary to our previous observation regarding BRCA1-associated breast cancer, BRCA2 tumors tended to be steroid receptor-positive, instead of steroid receptor-negative.

This study was supported by grant DDHK 95-953 from the Dutch Cancer Society.

This article has been cited by other articles:

				M. Leu, M. Reilly, and K. Czene Evaluation of Bias in Familial Risk Estimates: A Study of Common Cancers Using Swedish Population-based Registers J Natl Cancer Inst, September 17, 2008; 100(18): 1318 - 1325. [Abstract] [Full Text] [PDF]

				J. M. Lee, D. B. Kopans, P. M. McMahon, E. F. Halpern, P. D. Ryan, M. C. Weinstein, and G. S. Gazelle Breast Cancer Screening in BRCA1 Mutation Carriers: Effectiveness of MR Imaging--Markov Monte Carlo Decision Analysis Radiology, March 1, 2008; 246(3): 763 - 771. [Abstract] [Full Text] [PDF]

				B. A. M. Heemskerk-Gerritsen, C. T. M. Brekelmans, M. B. E. Menke-Pluymers, A. N. van Geel, M. M. A. Tilanus-Linthorst, C. C. M. Bartels, M. Tan, H. E. J. Meijers-Heijboer, J. G. M. Klijn, and C. Seynaeve Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic Ann. Surg. Oncol., December 1, 2007; 14(12): 3335 - 3344. [Abstract] [Full Text] [PDF]

				P van der Groep, A Bouter, R van der Zanden, I Siccama, F H Menko, J J P Gille, C van Kalken, E van der Wall, R H M Verheijen, and P J van Diest Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data J. Clin. Pathol., June 1, 2006; 59(6): 611 - 617. [Abstract] [Full Text] [PDF]

				C. E. Jacobi, N. J.D. Nagelkerke, J. C. van Houwelingen, and G. H. de Bock Breast Cancer Screening, Outside the Population-Screening Program, of Women from Breast Cancer Families without Proven BRCA1/BRCA2 Mutations: a Simulation Study. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 429 - 436. [Abstract] [Full Text] [PDF]

				M. H. Frost, J. M. Slezak, N. V. Tran, C. I. Williams, J. L. Johnson, J. E. Woods, P. M. Petty, J. H. Donohue, C. S. Grant, J. A. Sloan, et al. Satisfaction After Contralateral Prophylactic Mastectomy: The Significance of Mastectomy Type, Reconstructive Complications, and Body Appearance J. Clin. Oncol., November 1, 2005; 23(31): 7849 - 7856. [Abstract] [Full Text] [PDF]

				E. Kwiatkowska, M. Teresiak, V. Filas, A. Karczewska, D. Breborowicz, and A. Mackiewicz BRCA2 Mutations and Androgen Receptor Expression as Independent Predictors of Outcome of Male Breast Cancer Patients Clin. Cancer Res., October 1, 2003; 9(12): 4452 - 4459. [Abstract] [Full Text] [PDF]

				H. Meijers-Heijboer, C. T.M. Brekelmans, M. Menke-Pluymers, C. Seynaeve, A. Baalbergen, C. Burger, E. Crepin, A. W.M. van den Ouweland, B. van Geel, and J. G.M. Klijn Use of Genetic Testing and Prophylactic Mastectomy and Oophorectomy in Women With Breast or Ovarian Cancer From Families With a BRCA1 or BRCA2 Mutation J. Clin. Oncol., May 1, 2003; 21(9): 1675 - 1681. [Abstract] [Full Text] [PDF]

				V. G. Vogel, J. P. Costantino, D. L. Wickerham, and W. M. Cronin National Surgical Adjuvant Breast and Bowel Project Update: Prevention Trials and Endocrine Therapy of Ductal Carcinoma in Situ Clin. Cancer Res., January 1, 2003; 9(1): 495S - 501S. [Abstract] [Full Text] [PDF]

				E. L. Goode, A. M. Dunning, B. Kuschel, C. S. Healey, N. E. Day, B. A. J. Ponder, D. F. Easton, and P. P. D. Pharoah Effect of Germ-Line Genetic Variation on Breast Cancer Survival in a Population-based Study Cancer Res., June 1, 2002; 62(11): 3052 - 3057. [Abstract] [Full Text] [PDF]

				M. S. van Roosmalen, L. C.G. Verhoef, P. F.M. Stalmeier, N. Hoogerbrugge, and W. A.J. van Daal Decision Analysis of Prophylactic Surgery or Screening for BRCA1 Mutation Carriers: A More Prominent Role For Oophorectomy J. Clin. Oncol., April 15, 2002; 20(8): 2092 - 2100. [Abstract] [Full Text] [PDF]

				L. Scheuer, N. Kauff, M. Robson, B. Kelly, R. Barakat, J. Satagopan, N. Ellis, M. Hensley, J. Boyd, P. Borgen, et al. Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers J. Clin. Oncol., March 1, 2002; 20(5): 1260 - 1268. [Abstract] [Full Text] [PDF]

				S. Narod, K. Offit, M. Robson, D. Schrag, T. Riggs, M. J. Stoutjesdijk, J. O. Barentsz, J. G.M. Klijn, and H. Meijers-Heijboer Prophylactic Mastectomy in Carriers of BRCA Mutations N. Engl. J. Med., November 15, 2001; 345(20): 1498 - 1500. [Full Text] [PDF]

				M.-C. King, S. Wieand, K. Hale, M. Lee, T. Walsh, K. Owens, J. Tait, L. Ford, B. K. Dunn, J. Costantino, et al. Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial JAMA, November 14, 2001; 286(18): 2251 - 2256. [Abstract] [Full Text] [PDF]

				S. K. McDonnell, D. J. Schaid, J. L. Myers, C. S. Grant, J. H. Donohue, J. E. Woods, M. H. Frost, J. L. Johnson, D. L. Sitta, J. M. Slezak, et al. Efficacy of Contralateral Prophylactic Mastectomy in Women With a Personal and Family History of Breast Cancer J. Clin. Oncol., October 1, 2001; 19(19): 3938 - 3943. [Abstract] [Full Text]

				H. Meijers-Heijboer, B. van Geel, W. L.J. van Putten, S. C. Henzen-Logmans, C. Seynaeve, M. B.E. Menke-Pluymers, C. C.M. Bartels, L. C. Verhoog, A. M.W. van den Ouweland, M. F. Niermeijer, et al. Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation N. Engl. J. Med., July 19, 2001; 345(3): 159 - 164. [Abstract] [Full Text] [PDF]

				C.T.M. Brekelmans, C. Seynaeve, C.C.M. Bartels, M.M.A. Tilanus-Linthorst, E.J. Meijers-Heijboer, C.M.G. Crepin, A.N. van Geel, M. Menke, L.C. Verhoog, A. van den Ouweland, et al. Effectiveness of Breast Cancer Surveillance in BRCA1/2 Gene Mutation Carriers and Women With High Familial Risk J. Clin. Oncol., February 15, 2001; 19(4): 924 - 930. [Abstract] [Full Text] [PDF]

				P. O. Chappuis, L. Kapusta, L. R. Begin, N. Wong, J.-S. Brunet, S. A. Narod, J. Slingerland, and W. D. Foulkes Germline BRCA1/2 Mutations and p27Kip1 Protein Levels Independently Predict Outcome After Breast Cancer J. Clin. Oncol., December 15, 2000; 18(24): 4045 - 4052. [Abstract] [Full Text] [PDF]

				L. C. Verhoog, E. M. J. J. Berns, C. T. M. Brekelmans, C. Seynaeve, E. J. Meijers-Heijboer, and J. G. M. Klijn Prognostic Significance of Germline BRCA2 Mutations in Hereditary Breast Cancer Patients J. Clin. Oncol., November 1, 2000; 18(90001): 119s - 124. [Abstract] [Full Text] [PDF]

				R. T. Penson, M. V. Seiden, K. M. Shannon, M. L. Lubratovich, M. Roche, B. A. Chabner, and T. J. Lynch Jr. Communicating Genetic Risk: Pros, Cons, and Counsel Oncologist, April 1, 2000; 5(2): 152 - 161. [Abstract] [Full Text]

				D. A. Haber Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations: Tackling a Molecular and Clinical Conundrum J. Clin. Oncol., November 1, 1999; 17(11): 3367 - 3370. [Full Text] [PDF]